Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007637
DOI: 10.1136/jitc-2023-007637 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 17.10.2023. Verfasst von Philip Clingan und 25 weiteren Autor:innen. Beteiligte Einrichtung: Southern Medical Day Care Centre, Wollongong, New South Wales, Australia. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Checkpoint Therapeutics.
Abstract (Originalsprache)
Background
Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G1 subtype with a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, we present results of the pivotal study of patients with metastatic CSCC from an open-label, multicenter, multiregional, multicohort, phase 1 trial of cosibelimab.
Methods
In this trial, participants with metastatic CSCC received cosibelimab 800 mg intravenously every 2 weeks. Primary endpoint was objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, V.1.1. Secondary endpoints included duration of response (DOR) and safety.
Results
Objective response was observed in 37 of 78 participants (47.4% (95% CI: 36.0% to 59.1%)), with median follow-up of 15.4 months (range: 0.4 to 40.5) as of data cut-off. Median DOR was not reached (range: 1.4+ to 34.1+ months), with response ongoing in 73.0% of participants. Common treatment-emergent AEs (≥15%) were fatigue (26.9%), rash (16.7%), and anemia (15.4%). Eighteen participants (23.1%) experienced immune-related AEs (grade 3: n=2 (2.6%); no grade 4/5). No treatment-related deaths were reported.
Conclusions
Cosibelimab demonstrated clinically meaningful ORR and DOR and was associated with a manageable safety profile. Trial registration number NCT03212404 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Southern Medical Day Care Centre, Wollongong, New South Wales, Australia.
- Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.
- Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
- Christchurch Hospital, Christchurch, New Zealand.
- Medical Oncology, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
- Exellentis Clinical Trial Consultants, George, South Africa.
ORCID-Profile: Miguel-Angel Berciano-Guerrero, James Oliviero
Förderung
- Checkpoint Therapeutics
Zitieren
APA
Clingan, P., Ladwa, R., Brungs, D., Harris, D. L., McGrath, M., Arnold, S., Coward, J., Fourie, S., Kurochkin, A., Malan, D. R., Mant, A., Sharma, V., Shue, H., Tazbirkova, A., Berciano-Guerrero, M. A., Charoentum, C., Dalle, S., Dechaphunkul, A., Dudnichenko, O., …, & Desai, J. (2023). Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 11(10), e007637. https://doi.org/10.1136/jitc-2023-007637
Vancouver
Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007637. doi:10.1136/jitc-2023-007637
BibTeX
@article{Clingan2023,
author = {Clingan, Philip and Ladwa, Rahul and Brungs, Daniel and Harris, Dean Laurence and McGrath, Margaret and Arnold, Susan and Coward, Jermaine and Fourie, Samuel and Kurochkin, Andriy and Malan, Daniel R and Mant, Andrew and Sharma, Vinay and Shue, Hong and Tazbirkova, Andrea and Berciano-Guerrero, Miguel-Angel and Charoentum, Chaiyut and Dalle, Stéphane and Dechaphunkul, Arunee and Dudnichenko, Oleksandr and Koralewski, Piotr and Lugowska, Iwona and Montaudié, Henri and Muñoz-Couselo, Eva and Sriuranpong, Virote and Oliviero, James and Desai, Jayesh},
title = {Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {10},
pages = {e007637},
doi = {10.1136/jitc-2023-007637}
}
EUVIMED